THE ASSOCIATION BETWEEN FACTOR V LEIDEN, MTHFR C667T/A1298C POLYMORPHISMS AND PREGNANCY OUTCOMES
The present study aims to characterize the association between factor V Leiden, MTHFR C667T/A1298C polymorphisms and adverse pregnancy outcomes such as early recurrent pregnancy loss, thrombotic complications, fetal growth restriction, pre-eclamsia. Material and methods: We aimed to retrospectively assess the pregnancy outcomes of patients with factor V Leiden, MTHFR C667T/A1298C polymorphisms and their combination, between September 2019 and October 2020. Was determined the activity of protein C, antithrombin III and protein S activity. After isolation of blood DNA was evaluated Factor V Leiden, and MTHFR C667T/A1298C polymorphisms. Results: We segregated the 179 patients into 7 groups as follows: factor V Leiden mutation heterozygote and homozygote groups, patients with both factor V Leiden and MTHFR mutations, MTHFR A1298C polymorphism homozygote and heterozygote groups, and MTHFR C667T polymorphism homozygote and heterozygote groups. Although higher IVF rates were identified in the MTHFR C667T heterozygote group (23.9%) and in the FVL-homozygote group (33.3%), no statistically significant difference was calculated. Recurrent pregnancy losses were more frequently encountered in the FVL homozygote and FVL-MTHFR groups (66.6% and 66.7%), and we found a significant association between this parameter and patients with factor V Leiden and a combination of factor V Leiden - MTHFR polymorphisms (p<0.05). Conclusions: Our results suggest a strong association between factor V Leiden polymorphism, or between the combination of factor V Leiden and MTHFR polymorphism with adverse pregnancy outcomes such as thrombotic complications, early recurrent pregnancy loss and intrauterine growth restriction.
2. McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol 2012; 207(2): 135.e1-6.
3. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370(14): 1307-1315.
4. Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and Pregnancy Complications. Int J Mol Sci 2015; 16(12): 28418-28428.
5. Rambaldi MP, Mecacci F, Guaschino S, Paidas MJ. Inherited and acquired thrombophilias. Reprod Sci 2014; 21(2): 167-182.
6. Battinelli EM, Bauer KA. Thrombophilias in pregnancy. Hematol Oncol Clin North Am 2011; 25(2): 323-333, viii.
7. Franchini M, Lippi G. Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage? Semin Thromb Hemost. 2011; 37(3): 275-279.
8. Sergi C, Al Jishi T, Walker M. Factor V Leiden mutation in women with early recurrent pregnancy loss: a meta-analysis and systematic review of the causal association. Arch Gynecol Obstet 2015; 291(3): 671-679.
9. Cozaru GC, Aschie M, MitroI A, Brinzan C, Chisoi A. The Genetic Profile of Thrombophilia in Reproductive Disorders. Rev Chim 2019; 70(11): 3830-3834.
10. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87(10): 1095-1108.
11. Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JI. Thrombophilias and adverse pregnancy outcome - A confounded problem! Thromb Haemost 2008; 99(1): 77-85.
12. Corfield A, Meyer P, Kassam S, Mikuz G, Sergi C. SNPs: At the origins of the databases of an innovative biotechnology tool. Front Biosci (Schol Ed) 2010; 2: 1-4.
13. Dzimiri N, Meyer B. World distribution of factor V Leiden. Lancet 1996; 347(8999): 481-482.
14. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM: An International Journal of Medicine 2006; 99(5): 289-298.
15. Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and Bayesian meta-analysis. BMJ 2017; 359: j4452.
16. Kupferminc MJ. Thrombophilia and pregnancy. Reproductive Biology and Endocrinology 2003; 1(1): 111.
17. Howley HEA, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. American Journal of Obstetrics & Gynecology 2005; 192(3): 694-708.
18. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175(4 Pt 1): 902-905.
19. Rigó J, Jr., Nagy B, Fintor L. Factor V Leiden mutation and preeclampsia. American Journal of Obstetrics & Gynecology 2002; 186(4): 853.
20. Ahmed NA, Adam I, Elzaki SEG, Awooda HA, Hamdan HZ. Factor-V Leiden G1691A and prothrombin G20210A polymorphisms in Sudanese women with preeclampsia, a case control study. BMC Medical Genetics 2019; 20(1): 2 / doi: 10.1186/s12881-018-0737-z.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form